SCHEMBL2201199

SCHEMBL2201199

FC(F)(F)c1ccc(P(Cl)Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
KIF11 P52732 6/20 0.42
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
ORAI1 Q96D31 1/20 0.41
ORAI2 Q96SN7 1/20 0.41
ORAI3 Q9BRQ5 1/20 0.41
TRPV6 Q9H1D0 1/20 0.41
MGLL Q99685 1/20 0.41
PTPN1 P18031 1/20 0.39
GSK3B P49841 1/20 0.39
TAAR1 Q96RJ0 1/20 0.38
AHR P35869 1/20 0.38
EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL669274 0.84 ALDH1A1 (0.43) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL17448527 0.82 ALDH1A1 (0.42) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL669273 0.80 ALDH1A1 (0.40) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL287478 0.78 ALDH1A1 (0.48) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL15661104 0.78 ALDH1A1 (0.48) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL19514107 0.77 ALDH1A1 (0.42) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL63468 0.76 ALDH1A1 (0.67) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL6032229 0.76
SCHEMBL5713308 0.76 ALDH1A1 (0.46) ALDH1A1TSHRKIF11CES2CES1
SCHEMBL31325622 0.76 ALDH1A1 (0.46) ALDH1A1TSHRKIF11CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1354886-B1 Process for the preparation of tertiary phosphines SALTIGO GMBH (DE) 2009-08-26 EP claimed
US-7230136-B2 Reacting phosphorus halide with organomagnesium compound in presence of copper compound LANXESS DEUTSCHLAND GMBH (DE) 2007-06-12 US claimed
US-20030229240-A1 Reacting phosphorus halide with organomagnesium compound in presence of copper compound LANXESS DEUTSCHLAND GMBH (DE) 2003-12-11 US claimed
EP-1354886-A1 Process for the preparation of tertiary phosphines Bayer Aktiengesellschaft (DE) 2003-10-22 EP claimed
CN-112279940-B Acylphosphine photoinitiator and preparation method thereof 山东科技大学 2023-06-27 CN disclosed
CN-114957053-A Oxoethylene compound or pharmaceutically acceptable salt thereof, preparation method and application thereof, pharmaceutical composition and application thereof 中国医学科学院医药生物技术研究所 2022-08-30 CN disclosed
CN-110483576-B Phosphine-containing fused heterocyclic compound and preparation method and application thereof 宁波卢米蓝新材料有限公司 2022-03-18 CN disclosed
CN-112279940-A Acylphosphine photoinitiator and preparation method thereof 山东科技大学 2021-01-29 CN disclosed
US-20160016860-A1 METHODS FOR PHOSPHINE OXIDE REDUCTION IN CATALYTIC WITTIG REACTIONS DUBLIN CITY UNIVERSITY (IE) 2016-01-21 US disclosed
EP-2970347-A1 METHODS FOR PHOSPHINE OXIDE REDUCTION IN CATALYTIC WITTIG REACTIONS Dublin City University (IE) 2016-01-20 EP disclosed
WO-2014140353-A1 METHODS FOR PHOSPHINE OXIDE REDUCTION IN CATALYTIC WITTIG REACTIONS DUBLIN CITY UNIVERSITY (IE) 2014-09-18 WO disclosed
US-7977499-B2 Bis(ferrocenylphosphino) ferrocene ligands used in asymmetric hydrogenation reactions SOLVIAS AG (CH) 2011-07-12 US disclosed
US-20100160660-A1 BIS(FERROCENYLPHOSPHINO) FERROCENE LIGANDS USED IN ASSYMETRIC HYDROGENATION REACTIONS SOLVIAS AG (CH) 2010-06-24 US disclosed
EP-2125210-A1 BIS (FERROCENYLPHOSPHINO) FERROCENE LIGANDS USED IN ASYMMETRIC HYDROGENATION REACTIONS Solvias AG (CH) 2009-12-02 EP disclosed
EP-1354886-B1 Process for the preparation of tertiary phosphines SALTIGO GMBH (DE) 2009-08-26 EP disclosed
WO-2008101868-A1 BIS (FERROCENYLPHOSPHINO) FERROCENE LIGANDS USED IN ASYMMETRIC HYDROGENATION REACTIONS SOLVIAS AG (CH) 2008-08-28 WO disclosed
US-20070299273-A1 prepared by reacting phosphorus halide with organomagnesium compound in presence of copper compound; di(tert-butyl)phenylphosphonium tetrafluoroborate, for example LANXESS DEUTSCHLAND GMBH (DE) 2007-12-27 US disclosed
US-7230136-B2 Reacting phosphorus halide with organomagnesium compound in presence of copper compound LANXESS DEUTSCHLAND GMBH (DE) 2007-06-12 US disclosed
US-20030229240-A1 Reacting phosphorus halide with organomagnesium compound in presence of copper compound LANXESS DEUTSCHLAND GMBH (DE) 2003-12-11 US disclosed
EP-1354886-A1 Process for the preparation of tertiary phosphines Bayer Aktiengesellschaft (DE) 2003-10-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016860-A1 METHODS FOR PHOSPHINE OXIDE REDUCTION IN CATALYTIC WITTIG REACTIONS DCXR, TECR, PWWP2B ALDH1A1 4341/4885TSHR 707/4885KIF11 4432/4885
US-20100160660-A1 BIS(FERROCENYLPHOSPHINO) FERROCENE LIGANDS USED IN ASSYMETRIC HYDROGENATION REACTIONS FTH1, HRH4, HRH3 ALDH1A1 818/4885TSHR 724/4885KIF11 4436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.